Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Cellectis is a biotech company that engineers donated immune cells to fight cancer, aiming to create off-the-shelf cell therapies.
Cellectis is a clinical-stage biotech company that edits genes in immune cells to create "off-the-shelf" cancer treatments. Most cutting-edge cell therapies today are made from a patient's own cells, which is slow, expensive, and sometimes impossible. Cellectis instead starts with cells from healthy donors, uses gene-editing tools to modify them, and turns them into a ready-made medicine that can be pulled from a freezer and given to a patient.
The core idea is to engineer T cells鈥攖he immune system's killer cells鈥攕o they can hunt down cancer without attacking the patient's healthy body. The company's main programs use a gene-editing technology called TALEN to make these edits. Its lead candidate targets a type of leukemia and is being developed with partners, including a large collaboration with Allogene Therapeutics. Cellectis also has earlier-stage programs in other cancers and in gene therapy for rare diseases. Cellectis does not sell a product yet. It earns money mainly through partnerships and licensing deals with larger drugmakers, who pay upfront fees and fund research in exchange for rights to use its technology or share in future profits. That means the company is essentially a research engine fueled by partner cash and investor funding while it pushes its treatments through clinical trials.
The company is headquartered in Paris and has research and manufacturing operations in the United States. Its path is risky: cell therapy trials can fail, regulators can say no, and the field is crowded with rivals working on similar donor-derived approaches. But if Cellectis succeeds, it could offer something the industry badly wants鈥攑owerful cancer cell therapy that is cheaper, faster, and available to many patients instead of one at a time.
Saved answer 路 last researched 15 Nov 2026